{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-248083","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.967967+00:00","generated_at":"2026-05-30T07:39:00.870641+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Biomea Fusion: icovamenib boosts GLP-1 therapy insulin secretion; new oral GLP-1 RA BMF-650 shows early promise","bullets":["Preclinical ex vivo human islet data show icovamenib combined with tirzepatide or semaglutide more than doubles glucose-stimulated insulin secretion under hyperglycemic conditions.","Phase II COVALENT-211 study combining icovamenib with a GLP-1-based therapy planned to begin in 2025.","New oral small-molecule GLP-1 RA candidate BMF-650 exhibited higher bioavailability, less variable PK; estimated human dose ~100 mg once daily.","In cynomolgus monkeys, BMF-650 improved glucose control and significantly suppressed appetite over a six-day dosing period.","BMF-650 also enhanced glucose-stimulated insulin secretion in human donor islets, supporting potential for diabetes and obesity treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-248083","json":"https://secwatch.observer/filing/0001193125-24-248083.json","markdown":"https://secwatch.observer/filing/0001193125-24-248083.md","text":"https://secwatch.observer/filing/0001193125-24-248083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312524248083/0001193125-24-248083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312524248083/d850084d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:39:00.870641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}